Shares jump over 5% as Hims & Hers unveils plans for the first generic GLP-1--targeting Novo's weight-loss dominance ...

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today released a white paper ...

Hims & Hers is taking a more serious approach to its latest campaign. The telehealth company, which is best known for its ...

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...

Hims Hers Health Inc (NYSE:HIMS) reported third-quarter earnings that surpassed analyst expectations and raised its full-year ...

Since December 2023, Hims & Hers has provided its customers access to weight loss solutions. The Hims & Hers program offers a holistic, cost-effective, and personalized approach to reducing weight ...

Compounded semaglutide can be an affordable alternative to brand-name weight loss injections like Ozempic and Wegovy. But ...

It was Boxing Day 2003, when after seven months on Orlistat, the wonder weight-loss drug of the early noughties, Moira was ...

Hims & Hers today released a white paper on how its customers are thriving and seeing meaningful results through personalized weight loss solutions Hims & Hers Health, Inc. (“Hims & ...